"10.1371_journal.pone.0144270","plos one","2015-12-03T00:00:00Z","Nina L Cluny; Catherine M Keenan; Raylene A Reimer; Bernard Le Foll; Keith A Sharkey","Hotchkiss Brain Institute and Snyder Institute of Chronic Diseases, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada; Faculty of Kinesiology and Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada; Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada","Conceived and designed the experiments: NLC BLF KAS. Performed the experiments: NLC CMK. Analyzed the data: NLC CMK RAR. Contributed reagents/materials/analysis tools: RAR KAS. Wrote the paper: NLC RAR BLF KAS.","The authors of this manuscript have read the journals policy and have the following competing interests: Bernard Le Foll is doing some research on Sativex (a cannabinoid drug) for cannabis dependence that is funded by the Canadian Institutes of Health Research and the National Institutes of Health. GW Pharma is providing free drug samples of Sativex. All the other authors (Nina Cluny, Catherine Keenan, Raylene Reimer and Keith Sharkey) have declared that no competing interests exist. This does not alter the authorsâ€™ adherence to PLOS ONE policies on sharing data and materials.","2015","12","Nina L Cluny","NLC",5,FALSE,3,2,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
